Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.54 Million EUR | -74.11% |
| 2022 | 17.53 Million EUR | -4.08% |
| 2021 | 18.28 Million EUR | -27.38% |
| 2020 | 25.18 Million EUR | 35.98% |
| 2019 | 18.51 Million EUR | 278.46% |
| 2018 | 4.89 Million EUR | -15.35% |
| 2017 | 5.78 Million EUR | -7.98% |
| 2016 | 6.28 Million EUR | 794.73% |
| 2015 | 702 Thousand EUR | -3.57% |
| 2014 | 728 Thousand EUR | -59.87% |
| 2013 | 1.81 Million EUR | -11.34% |
| 2012 | 2.04 Million EUR | 13.67% |
| 2011 | 1.8 Million EUR | -13.46% |
| 2010 | 2.08 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 3.24 Million EUR | 0.0% |
| 2023 Q3 | 11.27 Million EUR | 7.15% |
| 2023 Q4 | 4.54 Million EUR | -59.72% |
| 2023 Q1 | 10.51 Million EUR | -40.03% |
| 2023 FY | 4.54 Million EUR | -74.11% |
| 2023 Q2 | 10.51 Million EUR | 0.0% |
| 2022 FY | 17.53 Million EUR | -4.08% |
| 2022 Q3 | 17.53 Million EUR | -20.52% |
| 2022 Q4 | 17.53 Million EUR | 0.0% |
| 2022 Q2 | 22.06 Million EUR | 0.0% |
| 2022 Q1 | 22.06 Million EUR | 20.68% |
| 2021 Q3 | 18.28 Million EUR | -25.83% |
| 2021 Q4 | 18.28 Million EUR | 0.0% |
| 2021 Q1 | 24.65 Million EUR | -2.1% |
| 2021 FY | 18.28 Million EUR | -27.38% |
| 2021 Q2 | 24.65 Million EUR | 0.0% |
| 2020 Q2 | 18.6 Million EUR | 0.0% |
| 2020 Q1 | 18.6 Million EUR | 0.44% |
| 2020 Q3 | 25.18 Million EUR | 35.38% |
| 2020 Q4 | 25.18 Million EUR | 0.0% |
| 2020 FY | 25.18 Million EUR | 35.98% |
| 2019 Q2 | 5.57 Million EUR | 0.0% |
| 2019 Q4 | 18.51 Million EUR | 0.0% |
| 2019 FY | 18.51 Million EUR | 278.46% |
| 2019 Q1 | 5.57 Million EUR | 13.84% |
| 2019 Q3 | 18.51 Million EUR | 232.46% |
| 2018 Q3 | 4.89 Million EUR | -9.99% |
| 2018 FY | 4.89 Million EUR | -15.35% |
| 2018 Q4 | 4.89 Million EUR | 0.02% |
| 2018 Q2 | 5.43 Million EUR | 0.0% |
| 2018 Q1 | 5.43 Million EUR | -5.97% |
| 2017 Q1 | 6.2 Million EUR | -1.29% |
| 2017 Q2 | 6.19 Million EUR | -0.02% |
| 2017 Q3 | 5.78 Million EUR | -6.74% |
| 2017 Q4 | 5.78 Million EUR | -0.02% |
| 2017 FY | 5.78 Million EUR | -7.98% |
| 2016 Q2 | 5.77 Million EUR | 0.02% |
| 2016 FY | 6.28 Million EUR | 794.73% |
| 2016 Q1 | 5.77 Million EUR | 722.65% |
| 2016 Q3 | 6.28 Million EUR | 8.74% |
| 2016 Q4 | 6.28 Million EUR | 0.0% |
| 2015 Q3 | 702 Thousand EUR | -10.0% |
| 2015 Q2 | 780 Thousand EUR | 0.0% |
| 2015 FY | 702 Thousand EUR | -3.57% |
| 2015 Q1 | 780 Thousand EUR | 7.14% |
| 2015 Q4 | 702 Thousand EUR | 0.0% |
| 2014 Q2 | 687 Thousand EUR | 0.0% |
| 2014 Q3 | 728 Thousand EUR | 5.97% |
| 2014 Q4 | 728 Thousand EUR | 0.0% |
| 2014 Q1 | 687 Thousand EUR | -62.13% |
| 2014 FY | 728 Thousand EUR | -59.87% |
| 2013 Q1 | 2 Million EUR | -2.15% |
| 2013 Q4 | 1.81 Million EUR | 0.0% |
| 2013 Q2 | 2 Million EUR | 0.0% |
| 2013 Q3 | 1.81 Million EUR | -9.39% |
| 2013 FY | 1.81 Million EUR | -11.34% |
| 2012 Q3 | 2.04 Million EUR | 0.0% |
| 2012 Q4 | 2.04 Million EUR | 0.0% |
| 2012 FY | 2.04 Million EUR | 13.67% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 FY | 1.8 Million EUR | -13.46% |
| 2011 Q4 | 1.8 Million EUR | 0.0% |
| 2010 FY | 2.08 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -312.352% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 89.843% |
| Aelis Farma SA | 2.04 Million EUR | -121.68% |
| Biophytis S.A. | 3.11 Million EUR | -45.934% |
| Advicenne S.A. | 15.89 Million EUR | 71.439% |
| genOway Société anonyme | 5.51 Million EUR | 17.743% |
| IntegraGen SA | 642.28 Thousand EUR | -606.857% |
| Medesis Pharma S.A. | 1.2 Million EUR | -278.333% |
| Neovacs S.A. | 650 Thousand EUR | -598.462% |
| NFL Biosciences SA | 39.2 Thousand EUR | -11480.746% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -4.212% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -131.594% |
| Sensorion SA | 1.24 Million EUR | -265.86% |
| Theranexus Société Anonyme | 2.46 Million EUR | -84.499% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -16.47% |
| TheraVet SA | 1 Million EUR | -353.728% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 34.26% |
| argenx SE | 15.35 Million EUR | 70.431% |
| BioSenic S.A. | 15.57 Million EUR | 70.847% |
| Celyad Oncology SA | 902 Thousand EUR | -403.326% |
| DBV Technologies S.A. | 4.52 Million USD | -0.309% |
| Galapagos NV | 4.94 Million EUR | 8.172% |
| Genfit S.A. | 62.25 Million EUR | 92.707% |
| GeNeuro SA | 6.49 Million EUR | 30.071% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -1219.767% |
| Innate Pharma S.A. | 30.6 Million EUR | 85.167% |
| Inventiva S.A. | 25.61 Million EUR | 82.277% |
| MaaT Pharma SA | 5.42 Million EUR | 16.313% |
| MedinCell S.A. | 52.8 Million EUR | 91.402% |
| Nanobiotix S.A. | 41.66 Million EUR | 89.102% |
| Onward Medical N.V. | 16.3 Million EUR | 72.157% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -31.571% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 87.214% |
| Oxurion NV | 117 Thousand EUR | -3780.342% |
| Pharming Group N.V. | 123.65 Million EUR | 96.329% |
| Poxel S.A. | 40.14 Million EUR | 88.69% |
| GenSight Biologics S.A. | 1.04 Million EUR | -333.206% |
| Transgene SA | 17 Thousand EUR | -26605.882% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.842% |
| Valneva SE | 132.76 Million EUR | 96.581% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |